PHILADELPHIA, July 23, 2025: Morgan Lewis advised MEI Pharma Inc. on the company’s private placement of 29,239,767 shares of common stock and prefunded warrants at a price of $3.42 per share. The aggregate gross proceeds of the placement total approximately $100 million. MEI Pharma will use the net proceeds to launch its treasury strategy focused on Litecoin, becoming the first and only publicly traded LTC holder on a national exchange.
MEI Pharma is a pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated therapies.
Partners Justin Chairman and Bryan Keighery and associate Maddy Anand represented MEI Pharma.